Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin versus gliclazide for hypoglycaemia in type 2 diabetes with chronic kidney disease
2015-002309-12Phase 4Completed
- Sponsor
- Imperial College London
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) comparing Continued gliclazide therapy with Linagliptin 5 mg (2 arms). Primary endpoint: Percent of time spent in hypoglycaemia. Started Mar 2016; status: completed.
02
Drugs
linagliptingliclazide
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2015-002309-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002309-12.